Document:

exv10w6

Exhibit 10.6

Execution Copy

ARBITRON
INC.

EXECUTIVE EMPLOYMENT AGREEMENT

     THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made March 2, 2009 by and between Arbitron
Inc., a Delaware corporation (the “Company”), and Dr. Robert Henrick, an individual (“you”) (and,
together, “Parties”).

     NOW THEREFORE, in consideration of your acceptance of employment, the Parties agree to be
bound by the terms contained in this Agreement as follows:

     1. Engagement. Beginning on a mutually satisfactory date no later than April 6, 2009 (the
“Effective Date”), the Company will employ you as Executive Vice President, Customer Solutions.
You will report directly to the President and Chief Executive Officer. You will be responsible for
research methods and product management. You will at all times comply with all policies of the
Company then in effect.

     2. Commitment. During and throughout the Employment Term (as defined in Section 3 below), you
must devote substantially all of your full working time and attention to the Company. During the
Employment Term, you must not engage in any employment, occupation, consulting or other activity
for direct or indirect financial remuneration unless approved by the President and Chief Executive
Officer and/or the Board of Directors of the Company (the “Board”); provided, however, that you
may, subject to compliance with the notice and consent requirements set forth in the Company’s
Corporate Governance Policies and Guidelines, (i) serve in any capacity with any professional,
community, industry, civic (including governmental boards), educational or charitable organization,
(ii) serve on for-profit entity board(s) having obtained prior consent and written approval from
the Board’s Nominating and Corporate Governance Committee, (iii) subject to the Company’s policies
applicable to all employees, make investments in other businesses and manage your and your family’s
personal investments and legal affairs and (iv) carry out the occasional transition duties you have
with the Johns Hopkins University Applied Physics Lab for up to 12 months following the Effective
Date; provided that any such activities described in clauses (i)-(iv) above do not materially
interfere with the discharge of your duties to the Company. You will perform your services under
this Agreement at the Company’s headquarters in Columbia, Maryland.

     3. Employment Term. You are an at-will employee. Your employment with the Company under this
Agreement will begin on the Effective Date and will continue until your employment terminates (such
employment period, the “Employment Term”).

     4. Cash and Stock Compensation.

          (a) Base Salary. During your employment hereunder, you will receive a base salary at a
monthly rate of $31,250, annualizing to $375,000 (“Base Salary”). The Company will pay your Base
Salary in accordance with the Company’s regular payroll practices. The

 

 

President and Chief Executive Officer will review your Base Salary no less frequently than
annually. If increased, the increased Base Salary will become the Base Salary for all purposes of
this Agreement. Your Base Salary will not be decreased without your written consent.

          (b) Incentive Bonus. Upon meeting the applicable performance criteria established by the
Company’s Compensation and Human Resources Committee of the Board (the “Compensation Committee”) in
its sole discretion, you will be eligible to receive an annual incentive bonus (the “Annual Bonus”)
for a given fiscal year of the Company targeted at an amount equal to 50% of your Base Salary in
effect at the beginning of such fiscal year (“Target Bonus”). For performance exceeding such
applicable performance criteria in the sole judgment of the Compensation Committee, the Annual
Bonus will be increased to an amount in excess of the Target Bonus up to a maximum of 150% of your
Base Salary in effect at the beginning of such fiscal year, which additional bonus amount the
Compensation Committee will determine in its sole discretion. The Annual Bonus, if any, will be
paid when other executives receive their bonuses under comparable arrangements but, in any event,
between January 1 and April 30 of the year following the year with respect to which it is earned.

          (c) Compensatory Stock Awards. Subject to the Compensation Committee’s approval, on or as
soon as administratively practicable following the Effective Date, the Company will grant you an
equity award to be valued at $1,300,000 on the date of grant, with the award divided by value into
(i) 75% stock options, and (ii) 25% restricted stock units, with respect to the Company’s common
stock, par value $0.50 (the “Common Stock”). The value for the options will be determined using
the Company’s standard Black-Scholes assumptions applied as of the date of grant and the value for
the restricted stock units will be determined by dividing the target value for the restricted stock
units by the Common Stock’s fair market value on the date of grant. The equity grants will either
be under a Company equity plan or under a special arrangement for you (in any case, referred to as
a “Stock Plan”). Assuming continued employment, the options under the grant will vest in equal
amounts on an annual basis over a three year period following the date of grant (beginning with
one-third on the first anniversary), and otherwise will contain the Company’s customary terms and
conditions for such grants, except as modified by this Agreement. Assuming continued employment,
the restricted stock units under the grant will vest in equal amounts on an annual basis over a
four year period following the date of grant (beginning with 25% on the first anniversary) and
otherwise will contain the Company’s customary terms and conditions for such grants, except as
modified by this Agreement. The Compensation Committee at its sole discretion will consider the
grant of additional compensatory stock awards to you.

     5. Employee Benefits.

          (a) Employee Welfare and Retirement Plans. You will, to the extent eligible, be entitled to
participate at a level commensurate with your position in all employee welfare benefit and
retirement plans and programs the Company provides to its executives in accordance with Company
policies. You will be covered under the Company’s Director and Officer liability insurance policy,
to the same extent as other officers.

          (b) Business Expenses. Upon submission of appropriate documentation in accordance with its
policies, the Company will promptly pay, or reimburse you, for all reasonable business expenses
that you incur in performing your duties under this Agreement, including, but not limited to,
travel, entertainment, professional dues and subscriptions, as long

- 2 -

 

as such expenses are reimbursable under the Company’s policies. Any payments or expenses provided
in this Section 5(b) will be paid in accordance with Section 7(c).

          (c) Paid Time Off. You will be entitled to paid time off in accordance with the standard
written policies of the Company with regard to executives.

     6. Termination of At-Will Employment.

          (a) General. Subject in each case to the provisions of this Section 6, nothing in this
Agreement interferes with or limits in any way the Company’s right to terminate your employment at
any time, for any reason or no reason, with or without notice, and nothing in this Agreement
confers on you any right to continue in the Company’s employ. If your employment ceases due to
death or for any other reason or for no reason, you will be entitled to receive (in addition to any
compensation and benefits you are entitled to receive under Section 6(b) or 6(c) below): (i) any
earned but unpaid Base Salary through and including the date of termination of your employment,
(ii) any earned but unpaid Annual Bonus, (iii) unreimbursed business expenses in accordance with
the Company’s policies; and (iv) any amounts or benefits to which you are then entitled under the
terms of the benefit plans then sponsored by the Company in accordance with their terms (and not
accelerated to the extent acceleration does not satisfy Section 409A of the Internal Revenue Code
of 1986, as amended (“Section 409A” of the “Code”)). Notwithstanding any other provision in this
Agreement to the contrary, any severance benefits to which you may be entitled will be provided
exclusively through the terms of this Section 6 of this Agreement.

          (b) Termination Without Cause; Resignation for Position Diminishment. If, during the
Employment Term, the Company terminates your employment without Cause (defined below) or you resign
as a result of Position Diminishment (defined below), you will be entitled to the following
severance benefits:

          (i) Cash Severance. Except as provided in Section 6(c), the Company will pay to you in
cash (i) an amount equal to 1.75 times your Base Salary on an annualized basis, paid in
equal installments over a 12 month period following the Effective Release Date (as defined
below) in accordance with the Company’s standard payroll policies and procedures and in a
manner not inconsistent with Section 7 hereof. Payment will cease if subsequent employment
is obtained prior to the end of the 12 month period.

          (ii) Benefits. The Company will also pay the full cost of the health care premiums
otherwise payable by you upon your election of health care continuation coverage for
yourself and your qualified beneficiaries as provided under the Consolidated Omnibus Budget
Reconciliation Act of 1985 (“COBRA”) until the earlier of 12 months or your ceasing to
qualify for COBRA coverage (such as by obtaining subsequent coverage).

          (iii) Release. To receive any severance benefits provided for under this Agreement or
otherwise, you must deliver to the Company of a general release of claims on the form the
Company provides, which must become irrevocable within 60 days following the date of your
termination of employment. Benefits will be paid or commence no later than 30 days after
such release becomes effective; provided, however,

- 3 -

 

that if the last day of the 60 day period for an effective release falls in the calendar
year following the year of your date of termination, the severance payments will be paid or
commence no earlier than January 1 of such subsequent calendar year. The date on which your
release of claims becomes effective is the “Effective Release Date.” You must continue to
comply with the covenants under Sections 8 and 9 below to continue to receive severance
benefits.

          (iv) “Position Diminishment” means (i) a change in your reporting responsibilities,
titles, duties, or offices as in effect as of the Effective Date (or, for purposes of
Section 6(c), as in effect immediately before a Change of Control), or any removal of you
from, or any failure to re-elect you to, any of such positions, that has the effect of
materially diminishing your responsibility, duties, or authority, (ii) a relocation of your
principal place of employment to a location more than 25 miles from its then current
location and that increases the distance from your primary residence by more than 25 miles,
or (iii) a material reduction in your Base Salary. You may only resign as a result of a
Position Diminishment if you (x) provide notice to the Company within 90 days following the
Date of Position Diminishment that you consider the Position Diminishment to be grounds to
resign; (y) provide the Company a period of 30 days to cure the Position Diminishment, and
(z) actually cease employment, if the Position Diminishment is not cured, by the six month
anniversary following the effective date of the Position Diminishment.

          (c) Change of Control. If, within 12 months following a Change of Control, your employment
ends on a termination without Cause or you resign for Position Diminishment, in addition to the
compensation and benefits described in Section 6(b)(ii) above (but in lieu of the compensation
under Section 6(b)(i) and subject to the release required under Section 6(b)(iii)), the Company
will pay to you in cash an amount equal to 2.625 times your Base Salary on an annualized basis,
paid in equal installments over a 12 month period following the Effective Release Date in
accordance with the Company’s standard payroll policies and procedures and in a manner not
inconsistent with Section 7 hereof. Payment will cease if subsequent employment is obtained prior
to the end of the 12 month period In addition, any outstanding equity compensation awards will
fully and immediately vest and, as applicable, become exercisable, provided that the Board will
have the right to suspend exercises or sales with respect to such equity compensation pending
satisfaction of the release requirement, and provided that the vesting will not accelerate the
distribution of shares underlying equity awards if such acceleration would trigger taxation under
Section 409A(a)(1)(B). The treatment in this Section 6(c) applies notwithstanding any contrary
provisions in the Stock Plan or any award agreement. For the purpose of this Agreement, “Change of
Control” means:

          (i) consummation of a merger or consolidation to which the Company is a party if the
individuals and entities who were stockholders of the Company immediately before the
effective date of such merger or consolidation have beneficial ownership (as defined in Rule
13d-3 under the Exchange Act) of less than 50% of the total combined voting power for
election of directors of the surviving Company immediately following the effective date of
such merger or consolidation; or

          (ii) the direct or indirect beneficial ownership (as defined in Rule 13d-3 under the
Exchange Act) in the aggregate of securities of the Company

- 4 -

 

representing 51% or more of the total combined voting power of the Company’s then
issued and outstanding securities by any person or entity, or group of associated persons or
entities acting in concert; provided, however, that for purposes hereof, any acquisition by
any employee benefit plan (or related trust) sponsored or maintained by the Company or any
corporation controlled by the Company will not constitute a Change of Control; or

          (iii) the direct or indirect beneficial ownership (as defined in Rule 13d-3 under the
Exchange Act) in the aggregate of securities of the Company representing 25% or more of the
total combined voting power of the Company’s then issued and outstanding securities by any
person or entity, or group of associated persons or entities acting in concert if such
acquisition is not approved by the Board before any such acquisition; provided, however ,
that for purposes hereof, any acquisition by any employee benefit plan (or related trust)
sponsored or maintained by the Company or any corporation controlled by the Company will not
constitute a Change of Control; or

          (iv) consummation of the sale of the properties and assets of the Company,
substantially as an entirety, to any person or entity which is not a wholly-owned subsidiary
of the Company; or

          (v) the liquidation of the Company is consummated; or

          (vi) a change in the composition of the Board at any time during any consecutive
24-month period such that the Continuity Directors cease for any reason to constitute at
least a 70 % majority of the Board. For purposes of this clause, “Continuity Directors”
means those members of the Board who either (A) were directors at the beginning of such
consecutive 24-month period, or (B) were elected by, or on the nomination or recommendation
of, at least a two-thirds majority of the then-existing Board.

          (d) Termination for Cause.

          (i) General. If, during the Employment Term, the Company terminates your employment
for Cause, you will be entitled only to the payments described in Section 6(a) (excluding,
on a termination for Cause, clause (ii) of Section 6(a)). You will have no further right to
receive any other compensation or benefits after such termination or resignation of
employment, except as determined in accordance with the terms of the employee benefit plans
or programs of the Company or as required by law.

          (ii) Cause. For purposes of this Agreement, “Cause” means termination of your
employment because of (i) fraud; (ii) misrepresentation; (iii) theft or embezzlement of
assets of the Company; (iv) your conviction, or plea of guilty or nolo contendere to any
felony (or to a felony charge reduced to a misdemeanor), or, with respect to your
employment, to any misdemeanor (other than a traffic violation), or your intentional
violations of law involving moral turpitude; (v) material failure to follow the Company’s
conduct and ethics policies; and/or (vi) your continued failure to attempt in good faith to
perform your duties as reasonably assigned by the Board to you for a period of 60 days after
a written demand for such performance that specifically identifies the

- 5 -

 

manner in which it is alleged you have not attempted in good faith to perform such
duties.

          (e) Death or Disability. Your employment hereunder will terminate immediately upon your
death, or if the Board, based upon appropriate medical evidence, determines you have become
physically or mentally incapacitated so as to render you incapable of performing your usual and
customary duties to the Company for a continuous period in excess of 180 days. Employment
termination under this subsection is not covered by Section 6(b) or 6(c).

          (f) Further Effect of Termination on Board and Officer Positions. If your employment ends for
any reason, you agree that you will cease immediately to hold any and all officer or director
positions you then have with the Company or any affiliate, absent a contrary direction from the
Board (which may include either a request to continue such service or a direction to cease serving
upon notice without regard to whether your employment has ended), except to the extent that you
reasonably and in good faith determine that ceasing to serve as a director would breach your
fiduciary duties to the Company. You hereby irrevocably appoint the Company to be your attorney to
execute any documents and do anything in your name to effect your ceasing to serve as a director
and officer of the Company and any subsidiary, should you fail to resign following a request from
the Company to do so. A written notification signed by a director or duly authorized officer of the
Company that any instrument, document or act falls within the authority conferred by this clause
will be conclusive evidence that it does so. The Company will prepare any documents, pay any filing
fees, and bear any other expenses related to this section.

     7. Effect of Section 409A of the Code.

          (a) Six Month Delay. If and to the extent any portion of any payment, compensation or other
benefit provided to you in connection with your separation from service (as defined in Section 409A
of Code) is determined to constitute “nonqualified deferred compensation” within the meaning of
Section 409A and you are a specified employee as defined in Section 409A(a)(2)(B)(i) of the Code,
as determined by the Company in accordance with its procedures, by which determination you hereby
agree that you are bound, such portion of the payment, compensation or other benefit will not be
paid before the earlier of (i) the day that is six months plus one day after the date of separation
from service (as determined under Section 409A) or (ii) the tenth (10th) day after the date of your
death (as applicable, the “New Payment Date”). The aggregate of any payments that otherwise would
have been paid to you during the period between the date of separation from service and the New
Payment Date will be paid to you in a lump sum in the first payroll period beginning after such New
Payment Date, and any remaining payments will be paid on their original schedule.

          (b) General 409A Principles. For purposes of this Agreement, each amount to be paid or
benefit to be provided will be construed as a separate identified payment for purposes of Section
409A, and any payments that are due within the “short term deferral period” as defined in Section
409A will not be treated as deferred compensation unless applicable law requires otherwise.
Neither the Company nor you will have the right to accelerate or defer the delivery of any such
payments or benefits except to the extent specifically permitted or required by Section 409A. This
Agreement is intended to comply with the provisions of Section 409A

- 6 -

 

and the Agreement will, to the extent practicable, be construed in accordance therewith. Terms
defined in the Agreement will have the meanings given such terms under Section 409A if and to the
extent required to comply with Section 409A. In any event, the Company makes no representations or
warranty and will have no liability to you or any other person, other than with respect to payments
made by the Company in violation of the provisions of this Agreement, if any provisions of or
payments under this Agreement are determined to constitute deferred compensation subject to Code
Section 409A but not to satisfy the conditions of that section.

          (c) Expense Timing. Payments with respect to reimbursements of business expenses will be made
in the ordinary course of business and in any case on or before the last day of the calendar year
following the calendar year in which the relevant expense is incurred. The amount of expenses
eligible for reimbursement during a calendar year may not affect the expenses eligible for
reimbursement in any other calendar year.

     8. Confidentiality, Disclosure, and Assignment

          (a) Confidentiality. You will not, during or after the Employment Period, publish, disclose,
or utilize in any manner any Confidential Information obtained while employed by the Company. If
you leave the Company’s employ, you will not, without the Company’s prior written consent, retain
or take away any drawing, writing, or other record in any form containing any Confidential
Information. For purposes of this Agreement, “Confidential Information” means information or
material of the Company that is not generally available to or used by others, or the utility or
value of which is not generally known or recognized as standard practice, whether or not the
underlying details are in the public domain, including:

          (i) information or material relating to the Company and its business as conducted or
anticipated to be conducted; business plans; operations; past, current or anticipated
software, products or services; customers or prospective customers; or research,
engineering, development, manufacturing, purchasing, accounting, or marketing activities;

          (ii) information or material relating to the Company’s inventions, improvements,
discoveries, “know-how,” technological developments, or unpublished writings or other works
of authorship, or to the materials, apparatus, processes, formulae, plans or methods used in
the development, manufacture or marketing of the Company’s software, products or services;

          (iii) information on or material relating to the Company that when received is marked
as “proprietary,” “private,” or “confidential”;

          (iv) the Company’s trade secrets;

          (v) software of the Company in various stages of development, including computer
programs in source code and binary code form, software designs, specifications, programming
aids (including “library subroutines” and productivity tools), interfaces, visual displays,
technical documentation, user manuals, data files and databases of the Company; and

- 7 -

 

          (vi) any similar information of the type described above that the Company obtained from
another party and that the Company treats as or designates as being proprietary, private or
confidential, whether or not owned or developed by the Company.

Notwithstanding the foregoing, “Confidential Information” does not include any information that is
properly published or in the public domain; provided, however, that information that is published
by or with your aid outside the scope of employment or contrary to the requirements of this
Agreement will not be considered to have been properly published, and therefore will not be in the
public domain for purposes of this Agreement.

          (b) Business Conduct and Ethics. During your employment with the Company, you will not engage
in any activity that may conflict with the Company’s interests, and you will comply with the
Company’s policies and guidelines pertaining to business conduct and ethics.

          (c) Disclosure. You will disclose promptly in writing to the Company all inventions,
discoveries, software, writings and other works of authorship that you conceived, made, discovered,
or written jointly or singly on Company time or on your own time during the period of your
employment by the Company, providing the invention, improvement, discovery, software, writing or
other work of authorship is capable of being used by the Company in the normal course of business,
and all such inventions, improvements, discoveries, software, writings and other works of
authorship shall belong solely to the Company.

          (d) Instruments of Assignment. You will sign and execute all instruments of assignment and
other papers to evidence vestiture of your entire right, title and interest in such inventions,
improvements, discoveries, software, writings or other works of authorship in the Company, at the
Company’s request and expense, and you will do all acts and sign all instruments of assignment and
other papers the Company may reasonably request relating to applications for patents, patents,
copyrights, and the enforcement and protection thereof. If you are needed, at any time, to give
testimony, evidence, or opinions in any litigation or proceeding involving any patents or
copyrights or applications for patents or copyrights, both domestic and foreign, relating to
inventions, improvements, discoveries, software, writings or other works of authorship you
conceived, developed or reduced to practice, you hereby agree to do so, and if you leave the
Company’s employ, the Company will pay you at an hourly rate mutually agreeable to the Company and
you, plus reasonable traveling or other expenses, subject to Section 7(c) of this Agreement.

          (e) Your Declaration. Except as provided in this subsection, you have no inventions, data
bases, improvements, discoveries, software, writings or other works of authorship useful to the
Company in the normal course of business that you conceived, made or wrote before the date of this
Agreement and that are excluded from this Agreement. The excepted invention is your interest in a
U.S. patent relating to music downloading, which you have disclosed to the Company.

          (e) Survival. The obligations of this Section 8 will survive the expiration or termination of
this Agreement and your employment.

- 8 -

 

     9. Non-Competition, Non-Recruitment, and Non-Disparagement.

          (a) General. The Parties recognize and agree that (a) you are becoming a senior executive of
the Company, (b) you will in the future receive substantial amounts of the Company’s confidential
information, (c) the Company’s business is conducted on a worldwide basis, and (d) provision for
non-competition, non-recruitment and non-disparagement obligations by you is critical to the
Company’s continued economic well-being and protection of the Company’s confidential information.
In light of these considerations, this Section 9 sets forth the terms and conditions of your
obligations of non-competition, non-recruitment, and non-disparagement during and subsequent to the
termination of this Agreement and/or the cessation of your employment for any reason.

          (b) Non-Competition.

               (i) Unless the Company waives or limits the obligation in accordance with Section
9(b)(ii), you agree that during employment and for the longest of 12 months following the
cessation of employment for any reason not covered by Section 6(b) or 6(c), 18 months if
Section 6(b) applies, and 24 months if Section 6(c) applies (the “Noncompete Period”), you
will not directly or indirectly, alone or as a partner, officer, director, shareholder or
employee of any other firm or entity, engage in any commercial activity in competition with
any part of the Company’s business as conducted as of the date of such termination of
employment or with any part of the Company’s contemplated business with respect to which you
have confidential information. For purposes of this clause (i), “shareholder” does not
include beneficial ownership of less than 5% of the combined voting power of all issued and
outstanding voting securities of a publicly held corporation whose stock is traded on a
major stock exchange. Also for purposes of this clause (i), “the Company’s business”
includes business conducted by the Company, its subsidiaries, or any partnership or joint
venture in which the Company directly or indirectly has ownership of not less than one third
of the voting equity. The Noncompete Period will be further extended by any period of time
during which you are in violation of Section 9(b). For purposes of this Section 9,
competitors of the Company currently include but are not limited to GfK AG, Integrated Media
Measurement, Inc., The Nielsen Company B.V., Taylor Nelson Sofres PLC, and WPP PLC.

               (ii) At its sole option the Company may, by written notice to you at any time within
the Noncompete Period, waive or limit the time and/or geographic area in which you cannot
engage in competitive activity.

               (iii) During the Noncompete Period, before accepting employment with or agreeing to
provide consulting services to, any firm or entity that offers competitive products or
services, you must give 30 days’ prior written notice to the Company. Such written notice
must be sent by certified mail, return receipt requested (attention: Office of the Chief
Legal Officer with a required copy to the Chair of Compensation Committee), must describe
the firm or entity and the employment or consulting services to be rendered to the firm or
entity, and must include a copy of the written offer of employment or engagement of
consulting services. The Company must respond or object to such notice within 30 days after
receipt, and the absence of a

- 9 -

 

response will constitute acquiescence or waiver of the Company’s rights under this Section
9.

          (c) Non-Recruitment. During employment and for a period of 12 months following cessation of
employment for any reason, you will not initiate or actively participate in any other employer’s
recruitment or hiring of the Company’s employees.

          (d) Non-Disparagement. You will not, during employment or after the termination or expiration
of this Agreement, make disparaging statements, in any form, about the Company, its officers,
directors, agents, employees, products or services that you know, or have reason to believe, are
false or misleading.

          (e) Enforcement. If you fail to provide notice to the Company under Section 9(b)(iii) and/or
in any way violate your obligations under Section 9, the Company may enforce all of its rights and
remedies provided to it under this Agreement, or in law and in equity, without the requirement to
post a bond, including without limitation ceasing any further payments to you under this Agreement,
and you will be deemed to have expressly waived any rights you may have had to payments under
Sections 6(b) or 6(c) or acceleration under Section 6(c).

          (f) Survival. The obligations of this Section 9 survive the expiration or termination of this
Agreement and your employment.

     10. Miscellaneous.

          (a) Notices. All notices, demands, requests or other communications required or permitted to
be given or made hereunder must be in writing and must be delivered, telecopied or mailed by first
class registered or certified mail, postage prepaid, addressed as follows:

	 	 	 	 	 
	 

	 	If to the Company:
	 	Arbitron Inc.
	 

	 	 	 	Office of Chief Legal Officer
	 

	 	 	 	9705 Patuxent Woods Drive
	 

	 	 	 	Columbia, MD 21046
	 
	 	 	 	 
	 

	 	If to you:
	 	At your last address on file with the Company

or to such other address as either party may designate in a notice to the other. Each notice,
demand, request or other communication that is given or made in the manner described above will be
treated as sufficiently given or made for all purposes three days after it is deposited in the U.S.
certified mail, postage prepaid, acceptance confirmation or at such time as it is delivered to the
addressee (with the return receipt, the delivery receipt, the answer back or the affidavit of
messenger being deemed conclusive evidence of such delivery) or at such time as delivery is refused
by the addressee upon presentation.

          (b) No Mitigation/No Offset. You are not required to seek other employment or otherwise
mitigate the value of any severance benefits contemplated by this Agreement, nor

- 10 -

 

will any such benefits be reduced by any earnings or benefits that you may receive from any
other source, except as provided in Section 6(b)(i). The amounts payable hereunder will not be
subject to setoff, counterclaim, recoupment, defense or other right which the Company may have
against you or others. Notwithstanding any other provision of this Agreement, any sum or sums paid
under this Agreement will be in lieu of any amounts to which you may otherwise be entitled under
the terms of any severance plan, policy, program, agreement or other arrangement sponsored by the
Company or an affiliate of the Company.

          (c) Waiver of Jury Trial. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE
WAIVED, THE PARTIES HEREBY WAIVE, AND COVENANT THAT THEY WILL NOT ASSERT (WHETHER AS PLAINTIFF,
DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT OR OTHER PROCEEDING ARISING
IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE RELEASE IT CONTEMPLATES,
WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE, THE
PARTIES AGREE THAT ANY PARTY MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE
OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE THEIR
RIGHTS TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS RELEASE OR TO
ANY OF THE MATTERS CONTEMPLATED UNDER THIS AGREEMENT, RELATING TO YOUR EMPLOYMENT, OR COVERED BY
THE CONTEMPLATED RELEASE.

          (d) Severability. Each provision of this Agreement must be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Agreement is held to be
prohibited by or invalid under applicable law, such provision will be ineffective only to the
extent of such prohibition or invalidity, without invalidating the remainder of such provision or
the remaining provisions of this Agreement. Moreover, if a court of competent jurisdiction
determines any of the provisions contained in this Agreement to be unenforceable because the
provision is excessively broad in scope, whether as to duration, activity, geographic application,
subject or otherwise, it will be construed, by limiting or reducing it to the extent legally
permitted, so as to be enforceable to the extent compatible with then applicable law to achieve the
intent of the Parties.

          (e) Assignment. This Agreement will be binding upon and will inure to the benefit of (i) your
heirs, beneficiaries, executors and legal representatives upon your death and (ii) this Agreement
will be binding upon any legal successor of the Company. Any legal successor of the Company will
be treated as substituted for the Company under the terms of this Agreement for all purposes. As
used herein, “successor” will mean any firm, corporation or other business entity that at any time,
whether by purchase or merger or otherwise, directly or indirectly acquires all or substantially
all of the assets or business of the Company.

     None of your rights to receive any form of compensation payable under this Agreement will be
assignable or transferable except through a testamentary disposition or by the laws of descent and
distribution upon your death or as provided in Section 10(h) hereof. Any attempted assignment,
transfer, conveyance or other disposition (other than as aforesaid) of any interest in your rights
to receive any form of compensation hereunder will be null and void; provided, however, that
notwithstanding the foregoing, you will be allowed to transfer vested shares

- 11 -

 

subject to stock options or the vested portion of other equity awards consistent with the rules for
transfers to “family members” as defined in Securities Act Form S-8.

          (f) No Oral Modification, Cancellation or Discharge. This Agreement may only be amended,
canceled or discharged in writing signed both by you and the Chair of the Compensation Committee of
the Board.

          (g) Survivorship. The respective rights and obligations of Company and you hereunder will
survive any termination of your employment to the extent necessary to the intended preservation of
such rights and obligations.

          (h) Beneficiaries. You will be entitled, to the extent applicable law permits, to select and
change the beneficiary or beneficiaries to receive any compensation or benefit payable hereunder
upon your death by giving the Company written notice thereof in a manner consistent with the terms
of any applicable plan documents. If you die, severance then due or other amounts due hereunder
will be paid to your designated beneficiary or beneficiaries.

          (i) Withholding. The Company will be entitled to withhold, or cause to be withheld, any
amount of federal, state, city or other withholding taxes or other amounts either required by law
or authorized by you with respect to payments made to you in connection with your employment
hereunder.

          (j) Company Policies. References in the Agreement to Company policies and procedures are to
those policies as they may be amended from time to time by the Company.

          (k) Governing Law. This Agreement must be construed, interpreted, and governed in accordance
with the laws of Maryland, without reference to rules relating to conflicts of law.

          (l) Entire Agreement. This Agreement and any documents referred to herein represent the
entire agreement of the Parties and will supersede any and all previous contracts, arrangements or
understandings between the Company and you.

Signatures on Page Following

- 12 -

 

     IN WITNESS WHEREOF, the Company has caused this Agreement to be duly executed and you have
hereunto set your hand, as of the day and year first above written, to be effective as of the
Effective Date.

	 	 	 	 	 
	ARBITRON INC.:	 	 
	 
	 	 	 	 
	By:

	 	/s/ Michael Skarzynski

 

	 	 
	 

	 	Michael Skarzynski	 	 
	 

	 	President and Chief Executive Officer	 	 
	 
	 	 	 	 
	EXECUTIVE:	 	 
	 
	 	 	 	 
	 
	 	/s/ Robert Henrick	 	 
	 

	 	 

Dr. Robert Henrick
	 	 

- 13 -exv10w1

Exhibit 10.1

Confidential treatment has been requested for the redacted portions. The confidential redacted

portions have been filed separately with the Securities and Exchange Commission.

DE-AC01-93NE50067,

08843672/50067-02

Amendment No. 018

     AMENDMENT No. 018, signed as of January 13, 2009, to Contract No. DE-AC01-
93NE50067, 08843672/50067-02 entered into January 14, 1994 (the “Contract”) by and between
United States Enrichment Corporation (“USEC”), Executive Agent of the Government of the
United States of America, and Joint Stock Company “Techsnabexport” (“TENEX”), Executive
Agent of the State Atomic Energy Agency “Rosatom”, Executive agent of the Government of the Russian
Federation. (USEC and TENEX, acting in their capacities as Executive Agents, are referred to herein
individually as a “Party” and collectively as the “Parties”). Capitalized terms
used but not defined herein shall have the meanings ascribed to such terms in the Contract.

     Pursuant to Part 1, Section H.04 of the Contract, USEC and TENEX hereby agree as follows:

     SECTION 1. In accordance with the Contract, USEC shall pay a per SWU price of ***** for the
SWU component of ***** of low enriched uranium (“LEU”) to be delivered to USEC under the
Contract in calendar year (“CY”) 2009 pursuant to the USEC delivery order attached hereto
as Appendix A (the “CY2009 Delivery Order”.)

     SECTION 2. Without reducing the quantities to be delivered in CY2009 under the Contract, the
Parties shall adjust the parameters of the CY2009 Delivery Order and the month-by-month schedule of
deliveries attached thereto to take account the following issues: (1) commitments of the Executive
Agent of the Russian Federation to provide a certain revenue to the Federal Budget of the Russian
Federation in CY2009; (2) production commitments of Russian enrichment facilities; and/or (3)
logistical problems for TENEX or USEC. The deliveries of LEU in CY2009 shall begin in accordance
with the adjusted CY2009 Delivery Order and the month-by-month schedule of deliveries upon their
approval by Rosatom and the signing thereof by the Parties. The purchase price set forth in
Section 1 of this Amendment shall be paid by USEC for all of the SWU component of LEU subject to
delivery to USEC of LEU in accordance with the adjusted CY2009 Delivery Order.

     SECTION 3. In the event that this Amendment enters into force and effect, the Parties shall
use their good faith efforts to reach agreement, not later than March 15, 2009, on a new price
determination methodology for the SWU component of the LEU to be delivered to USEC under the
Contract pursuant to USEC delivery orders for the period from, and including, CY2010 through the
remaining term of the Contract, and shall use their best efforts to promptly secure the approval or
endorsement by the Government of the Russian Federation and the Government of the United States of
America of an amendment to the Contract incorporating such methodology.

     SECTION 4. Except as expressly amended hereby, the Contract shall remain unchanged and in
full force and effect.

 

 

     SECTION 5. This Amendment may be executed in two or more counterparts, each of which
shall constitute an original, but all of which, when taken together, shall constitute one and the
same instrument.

     SECTION 6. This Amendment shall enter into force and effect, the rights and obligations of
the Parties under this Amendment shall arise and the Parties shall be bound by the obligations and
entitled to the rights as set forth in this Amendment upon and as of the first day by which (i) the
approval or endorsement of this Amendment by the Government of the Russian Federation or its
authorized agency(ies) of the Government of the Russian Federation has been obtained and
(ii) written confirmation that USEC, as the Executive Agent for the Government of the United States
of America, is authorized to sign this Amendment (or confirmation that the approval of the U.S.
Government is not required) has been obtained from the U.S. State Department as the authorized
agency of the U.S. Government. TENEX shall notify USEC as soon as such approval or endorsement of
the Government of the Russian Federation or its authorized agency(ies) has been obtained and USEC
shall notify TENEX as soon as such written confirmation has been obtained from the U.S. State
Department. Each Party shall use its best efforts to secure, as soon as possible, the approval,
endorsement or confirmation, as applicable, of its respective government.

     IN WITNESS WHEREOF, the Parties hereto have executed this Amendment as of the date first
written above.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	UNITED STATES ENRICHMENT
CORPORATION	 	 	 	JOINT STOCK COMPANY
“TECHSNABEXPORT”	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Philip G. Sewell	 	 	 	By:	 	/s/ Alexey A. Grigoriev	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Philip G. Sewell
	 	 	 	 	 	Name:
	 	Alexey A. Grigoriev	 	 
	 

	 	Title:
	 	Senior Vice President
	 	 	 	 	 	Title:
	 	General Director	 	 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]